Table 6 Clinical trials of anti-LAG-3, anti-TIM-3, anti-TIGIT BsAbs
From: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Clinical trial identifier | Phase | Start date | Status | Cancer type (population, N) | Interventions and combination | Target | Primary outcome measures | Secondary outcome measures |
|---|---|---|---|---|---|---|---|---|
NCT03219268 | I | Aug 18, 2017 | Completed | Unresectable or Metastatic Neoplasms, N = 353 | Tebotelimab (MGD013) | LAG-3 PD-1 | TEAEs, etc | AUC, Cmax, etc |
NCT04082364 | II/III | Sep 30, 2019 | Active, not recruiting | GC, GEJC, HER2 + GC, N = 82 | ORR, CR, PR, etc | ADA, etc | ||
NCT04634825 | II | Mar 17, 2021 | Terminated | HNC, HNSCC, N = 62 | ORR, CR, etc | BOR, Cmax, etc | ||
NCT05419388 | I/II | Aug 15, 2022 | Recruiting | Melanoma, N = 80 | RO7247669 | LAG-3 PD-1 | PFS | ORR, DOR, etc |
NCT05645692 | II | Apr 13, 2023 | Recruiting | UC, N = 240 | ORR | OS, DCR, etc | ||
NCT04140500 | I/II | Nov 11, 2019 | Recruiting | Solid tumor, NSCLC, metastatic melanoma, N = 320 | DLTs, ORR, etc | Cmax, AUC, etc | ||
NCT04785820 | II | Jun 25, 2021 | Recruiting | AMESCC, N = 210 | OS | ORR, DCR, etc | ||
NCT05805501 | II | Apr 21, 2023 | Recruiting | RCC, N = 210 | PFS | OS, ORR, etc | ||
NCT05775289 | II | Mar 15, 2023 | Recruiting | NSCLC, N = 180 | PFS, ORR | OS, DOR, etc | ||
NCT04524871 | I/II | Nov 2, 2020 | Recruiting | Advanced LC, N = 400 | ORR | PFS, OS, etc | ||
NCT03440437 | I/II | Apr 16, 2018 | Recruiting | AMC, HNSCC, N = 80 | FS118 | LAG-3 PD-L1 | AUC, CL, etc | Cmax, Tmax, etc |
NCT04618393 | I/II | Mar 11, 2021 | Recruiting | Advanced solid tumors, N = 43 | EMB-02 | LAG-3 PD-1 | SAEs, ORR, etc | AUC, Cmax, etc |
NCT04916119 | I | Jun 29, 2021 | Recruiting | Advanced malignancies, N = 322 | IBI323 | LAG-3 PD-L1 | AEs, etc | ORR, DCR, etc |
NCT03849469 | I | May 29, 2019 | Completed | Melanoma, CESC, PAAD, TNBC, HCC, BLCA, etc, N = 78 | XmAb22841 | LAG-3 CTLA-4 | AEs | – |
NCT05695898 | I/II | Feb 28, 2023 | Recruiting | AM Melanoma, N = 46 | AEs, DLTs, etc | AUC, Cmin, etc | ||
NCT03752177 | Ia/Ib | Nov 22, 2018 | Terminated | Advanced Solid Tumors, N = 12 | LY3415244 | TIM-3 PD-L1 | DLTs | ORR, DOR, etc |
NCT03708328 | I | Oct 15, 2018 | Active, not recruiting | Advanced and/or metastatic solid tumors, N = 134 | Lomvastomig (R07121661) | TIM-3 PD-1 | DLTs, etc | AUC, Cmax, etc |
NCT04785820 | II | Jun 25, 2021 | Recruiting | AMESCC, N = 210 | Lomvastomig (R07121661) | TIM-3 PD-1 | OS | ORR, DOR, etc |
NCT04931654 | I/IIa | Sep 28, 2021 | Recruiting | NSCLC, other AST, N = 81 | AZD7789 | TIM-3 PD-1 | AEs, DLTs, etc | OS, etc |
NCT05216835 | I/II | Mar 18, 2022 | Recruiting | R/R HL, N = 180 | AZD7789 | TIM-3 PD-1 | AEs, DLTs, etc | CRR, ORR, etc |
NCT05357651 | I | Aug 12, 2022 | Recruiting | Advanced solid tumors or lymphoma, N = 100 | LB1410 | TIM-3 PD-1 | TEAEs, SAEs, etc | ORR, DCR, etc |
NCT05005442 | II | Sep 28, 2021 | Recruiting | HMs, N = 180 | MK-7684A | TIGIT PD-1 | DLTs, AEs | ORR, DOR, etc |
NCT04911881 | Ia | Jun 24, 2021 | Completed | Advanced solid tumors, N = 36 | IBI321 | TIGIT PD-1 | DLTs, TRAE | ORR, PFS, etc |
NCT04911894 | I | Jun 21, 2021 | Completed | Advanced solid tumors, N = 16 | AEs, DLTs | DOR, PFS, etc | ||
NCT04995523 | I/II | Sep 14, 2021 | Recruiting | NSCLC, N = 192 | AZD2936 | TIGIT PD-1 | AEs, DLTs, ORR | DCR, DOR, etc |
CTR20220021 | II | Nov 5, 2021 | Recruiting | Advanced solid tumors, N = 30 | ZG005 | TIGIT PD-1 | DLTs, AEs | DCR, DOR, etc |
NCT05025085 | I | Oct 4,2021 | Active, not recruiting | Advanced cancer, N = 70 | AGEN1777 | TIGIT an undisclosed target | DLTs, TEAEs | ADA, CR, etc |